JP2018512047A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512047A5 JP2018512047A5 JP2017557481A JP2017557481A JP2018512047A5 JP 2018512047 A5 JP2018512047 A5 JP 2018512047A5 JP 2017557481 A JP2017557481 A JP 2017557481A JP 2017557481 A JP2017557481 A JP 2017557481A JP 2018512047 A5 JP2018512047 A5 JP 2018512047A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cells
- tcr
- modified
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 21
- 210000000822 natural killer cell Anatomy 0.000 claims 15
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 238000009172 cell transfer therapy Methods 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000002163 immunogen Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 210000005260 human cell Anatomy 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1501175.2 | 2015-01-23 | ||
| GBGB1501175.2A GB201501175D0 (en) | 2015-01-23 | 2015-01-23 | A universal T-cell for personalised medicine |
| PCT/EP2016/051344 WO2016116601A1 (en) | 2015-01-23 | 2016-01-22 | Universal killer t-cell |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512047A JP2018512047A (ja) | 2018-05-10 |
| JP2018512047A5 true JP2018512047A5 (OSRAM) | 2019-03-07 |
| JP6899333B2 JP6899333B2 (ja) | 2021-07-07 |
Family
ID=52673865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017557481A Active JP6899333B2 (ja) | 2015-01-23 | 2016-01-22 | 汎用キラーｔ細胞 |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11155786B2 (OSRAM) |
| EP (2) | EP4095239A1 (OSRAM) |
| JP (1) | JP6899333B2 (OSRAM) |
| KR (1) | KR102479118B1 (OSRAM) |
| CN (1) | CN107250351A (OSRAM) |
| AU (2) | AU2016208475B2 (OSRAM) |
| CA (1) | CA2973924C (OSRAM) |
| DK (1) | DK3247791T3 (OSRAM) |
| EA (1) | EA201791381A1 (OSRAM) |
| ES (1) | ES2922231T3 (OSRAM) |
| GB (1) | GB201501175D0 (OSRAM) |
| IL (1) | IL253464B (OSRAM) |
| MX (1) | MX390756B (OSRAM) |
| PL (1) | PL3247791T3 (OSRAM) |
| PT (1) | PT3247791T (OSRAM) |
| SG (1) | SG11201705693XA (OSRAM) |
| WO (1) | WO2016116601A1 (OSRAM) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201501175D0 (en) * | 2015-01-23 | 2015-03-11 | Univ Oslo Hf | A universal T-cell for personalised medicine |
| EP3466967A1 (en) | 2015-05-18 | 2019-04-10 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| WO2017192440A1 (en) * | 2016-05-02 | 2017-11-09 | Cerus Corporation | Compositions and methods for improved nk cell therapies |
| AU2017306432A1 (en) | 2016-08-02 | 2019-03-21 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
| BR112019007100A2 (pt) | 2016-10-07 | 2019-06-25 | Tcr2 Therapeutics Inc | composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão |
| CA3044593A1 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| US20190358263A1 (en) | 2016-12-07 | 2019-11-28 | Oslo Universitetssykehus Hf | Compositions and Methods for Cell Therapy |
| WO2018129199A1 (en) * | 2017-01-04 | 2018-07-12 | Nova Southeastern University | Natural killer (nk) cells expressing an antigen-specific functional t cell receptor (tcr) complex, methods for production thereof, and methods for therapeutic use thereof |
| GB201803178D0 (en) | 2018-02-27 | 2018-04-11 | Univ Oslo Hf | Specific binding molecules for htert |
| SG11202101851WA (en) * | 2018-08-31 | 2021-03-30 | Invectys SA | Method to assess car functionality |
| WO2020191358A1 (en) * | 2019-03-20 | 2020-09-24 | Bluebird Bio, Inc. | Adoptive cell therapy |
| JP6977969B2 (ja) * | 2019-03-22 | 2021-12-08 | 株式会社ガイアバイオメディシン | 免疫細胞提供システム |
| EP3750547A1 (en) | 2019-06-13 | 2020-12-16 | Universitätsmedizin der Johannes Gutenberg-Universität Mainz | Modified nk-92 cells, and therapeutic and diagnostic uses thereof |
| CN115052965A (zh) | 2019-07-29 | 2022-09-13 | 麻省理工学院 | 用于器官发生的合成水凝胶 |
| CN111662871A (zh) * | 2020-06-11 | 2020-09-15 | 福建医科大学孟超肝胆医院(福州市传染病医院) | 一种核酸适体功能化nk细胞及其制备与应用 |
| CA3193353A1 (en) | 2020-09-24 | 2022-03-31 | Carina WEHNER | Prame specific t-cell receptors and uses thereof |
| TW202233831A (zh) * | 2020-11-03 | 2022-09-01 | 中國大陸商杭州啟函生物科技有限公司 | 增強免疫療法的系統和方法 |
| GB202017873D0 (en) | 2020-11-12 | 2020-12-30 | Olso Unversitetssykehus Hf | Method of determining DLBCL prognosis |
| WO2022250312A1 (ko) * | 2021-05-27 | 2022-12-01 | (주)에스엠티바이오 | 신경내분비종양의 치료용 자연살해세포 |
| CN118215498A (zh) | 2021-09-21 | 2024-06-18 | 奥斯陆大学医院Hf | 末端脱氧核苷酸转移酶(TdT)的结合蛋白 |
| WO2023078287A1 (en) * | 2021-11-03 | 2023-05-11 | Hangzhou Qihan Biotechnology Co., Ltd. | Systems and methods for enhanced immunotherapies |
| EP4558152A2 (en) * | 2022-07-22 | 2025-05-28 | Board of Regents, The University of Texas System | Cd3-expressing natural killer cells with enhanced function for adoptive immunotherapy |
| WO2024261045A1 (en) | 2023-06-20 | 2024-12-26 | Zelluna Immunotherapy As | Methods of enhancing or modifying nk cells |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5124251A (en) | 1990-01-31 | 1992-06-23 | Becton, Dickinson And Company | CD3 ζ co-associated complex on CD16- NK cells |
| AU7267398A (en) | 1997-04-30 | 1998-11-24 | Hans Klingemann | Natural killer cell lines and methods of use |
| IL127142A0 (en) | 1998-11-19 | 1999-09-22 | Yeda Res & Dev | Immune cells having predefined biological specificity |
| JP4716350B2 (ja) | 2001-12-04 | 2011-07-06 | ダナ−ファーバー キャンサー インスティテュート インク． | 潜伏期膜タンパク質に対する抗体およびそれらの使用 |
| DE602005016683D1 (de) * | 2004-07-10 | 2009-10-29 | Fox Chase Cancer Ct | Genetisch modifizierte, menschliche, natürliche killerzellenlinien: |
| US20090104170A1 (en) * | 2004-11-02 | 2009-04-23 | Richard William Wyatt Childs | Compositions and methods for treating hyperproliferative disorders |
| US8518697B2 (en) | 2006-04-04 | 2013-08-27 | Washington University | Single chain trimers and uses therefor |
| CN101631138A (zh) | 2008-07-18 | 2010-01-20 | 深圳富泰宏精密工业有限公司 | 个人信息代理系统及方法 |
| WO2010088160A1 (en) * | 2009-01-28 | 2010-08-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | T cell receptors and related materials and methods of use |
| WO2013126785A1 (en) * | 2012-02-22 | 2013-08-29 | Ingenium Biotherapy Corporation | A system for immunotherapy targeting tumor propagation and progression |
| US11471486B2 (en) | 2012-09-04 | 2022-10-18 | Inven2 As | Selective and controlled expansion of educated NK cells |
| US9511092B2 (en) | 2013-01-28 | 2016-12-06 | St. Jude Children's Research Hospital, Inc. | Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease |
| EP2951302B1 (en) | 2013-02-04 | 2019-01-02 | Roger Williams Medical Center | Methods and compositions for treating gastrointestinal stromal tumor(gist) |
| JP6425301B2 (ja) * | 2014-05-29 | 2018-11-21 | 国立大学法人富山大学 | Ｔｃｒの細胞傷害活性誘導能を評価するためのｎｋ細胞株、およびその作製方法 |
| KR20170018450A (ko) | 2014-06-18 | 2017-02-17 | 케모테라포이티쉐스 포르슝스인스티투트 게오르크-스파이어-하우스 | 세포 치료제로서의 car-발현 nk-92 세포 |
| US20170274014A1 (en) * | 2014-07-21 | 2017-09-28 | Jennifer Brogdon | Combinations of low, immune enhancing, doses of mtor inhibitors and cars |
| GB201501175D0 (en) * | 2015-01-23 | 2015-03-11 | Univ Oslo Hf | A universal T-cell for personalised medicine |
-
2015
- 2015-01-23 GB GBGB1501175.2A patent/GB201501175D0/en not_active Ceased
-
2016
- 2016-01-22 EA EA201791381A patent/EA201791381A1/ru unknown
- 2016-01-22 MX MX2017009459A patent/MX390756B/es unknown
- 2016-01-22 CA CA2973924A patent/CA2973924C/en active Active
- 2016-01-22 SG SG11201705693XA patent/SG11201705693XA/en unknown
- 2016-01-22 PL PL16701339.0T patent/PL3247791T3/pl unknown
- 2016-01-22 EP EP22170488.5A patent/EP4095239A1/en active Pending
- 2016-01-22 JP JP2017557481A patent/JP6899333B2/ja active Active
- 2016-01-22 WO PCT/EP2016/051344 patent/WO2016116601A1/en not_active Ceased
- 2016-01-22 CN CN201680006587.4A patent/CN107250351A/zh active Pending
- 2016-01-22 PT PT167013390T patent/PT3247791T/pt unknown
- 2016-01-22 AU AU2016208475A patent/AU2016208475B2/en active Active
- 2016-01-22 ES ES16701339T patent/ES2922231T3/es active Active
- 2016-01-22 US US15/545,021 patent/US11155786B2/en active Active
- 2016-01-22 DK DK16701339.0T patent/DK3247791T3/da active
- 2016-01-22 KR KR1020177023284A patent/KR102479118B1/ko active Active
- 2016-01-22 EP EP16701339.0A patent/EP3247791B1/en active Active
-
2017
- 2017-07-13 IL IL253464A patent/IL253464B/en unknown
-
2021
- 2021-09-23 US US17/483,484 patent/US20220127574A1/en not_active Abandoned
-
2022
- 2022-01-11 AU AU2022200126A patent/AU2022200126A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018512047A5 (OSRAM) | ||
| WO2019222275A3 (en) | Compositions and methods for tcr reprogramming using inducible fusion proteins | |
| Lohmueller et al. | Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines | |
| WO2018098365A3 (en) | Compositions and methods for tcr reprogramming using fusion proteins | |
| CN110177558B (zh) | 用于病毒特异性t细胞的活化和扩增的平台 | |
| JP2016501013A5 (OSRAM) | ||
| JP2021176866A (ja) | 共通ネオ抗原 | |
| WO2020021045A3 (en) | Therapeutic preparations of gamma-delta t cells and natural killer cells and methods for manufacture and use | |
| WO2012142529A3 (en) | Clonal strains of attenuated vaccinia viruses and methods of use thereof | |
| JP2016512199A5 (OSRAM) | ||
| WO2013120012A3 (en) | Cdim binding proteins and uses thereof | |
| JP2018512161A5 (OSRAM) | ||
| JP2019504892A5 (OSRAM) | ||
| BR112018068391A2 (pt) | sistema e métodos para produzir uma proteína, célula inoculada, construção de rna para expressar a replicase de alfavírus e dna | |
| FI3102609T3 (fi) | Menetelmiä b-solukasvaimien ja muiden syöpien hoidossa käyttökelpoisten autologisten t-solujen ja niiden koostumusten valmistamiseksi | |
| JP2016539929A5 (OSRAM) | ||
| EP4545639A3 (en) | Engineered gamma delta t-cells | |
| BR112014015016A8 (pt) | Proteína homodimérica de duas cadeias de aminoácidos idênticas, cadeia de aminoácido, molécula de ácido nucléico, composição farmacêutica, célula hospedeira, método de preparação de uma proteína homodimérica, método para preparação de uma vacina, vacina e método de tratamento ou prevenção | |
| WO2018005521A3 (en) | Cell culture chambers and methods of use thereof | |
| JP2013537426A5 (OSRAM) | ||
| JP2019508044A5 (OSRAM) | ||
| JP2018531016A5 (OSRAM) | ||
| Zhu et al. | Decitabine before low-dose cytarabine-based chemotherapy combined with human leukocyte antigen–mismatched stem cell microtransplantation improved outcomes in elderly patients with newly diagnosed acute myeloid leukemia | |
| Biondi et al. | Redirecting T cells with Chimeric Antigen Receptor (CAR) for the treatment of childhood acute lymphoblastic leukemia | |
| JP2014515258A5 (OSRAM) |